Clinical Trial Update: A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial of ixekizumab in moderate-to-severe genital psoriasis has completed; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Psoriasis
• Psoriasis

Drugs mentioned

• Ixekizumab (ixekizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Genital Psoriasis, Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2018-03-23